

Walid L Shaib

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2101855/publications.pdf>

Version: 2024-02-01

63
papers

1,733
citations

318942

23
h-index

340414

39
g-index

63
all docs

63
docs citations

63
times ranked

3182
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors. <i>Oncology</i> , 2022, 100, 131-139.	0.9	5
2	Survival Outcomes of Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer. <i>Oncologist</i> , 2022, 27, 740-750.	1.9	2
3	Is adjuvant chemotherapy beneficial for stage II-III goblet cell carcinoid/goblet cell adenocarcinoma of the appendix?. <i>Surgical Oncology</i> , 2021, 36, 120-129.	0.8	7
4	Perioperative therapy in metastatic colorectal cancer: Pattern of use and survival outcomes. <i>Journal of Surgical Oncology</i> , 2021, 123, 596-605.	0.8	3
5	Impact of high-risk features for stage II adenocarcinoma of the appendix. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100329.	0.7	1
6	Impact of Tumor Side on Clinical Outcomes in Stage II and III Colon Cancer With Known Microsatellite Instability Status. <i>Frontiers in Oncology</i> , 2021, 11, 592351.	1.3	9
7	Survival Outcomes of Acinar Cell Pancreatic Cancer. <i>Pancreas</i> , 2021, 50, 529-536.	0.5	1
8	Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies. <i>Targeted Oncology</i> , 2021, 16, 461-469.	1.7	14
9	Safety and Efficacy of 7 Days on/7 Days off Versus 14 Days on/7 Days off Schedules of Capecitabine in Patients with Metastatic Colorectal Cancer: A Retrospective Review. <i>Clinical Colorectal Cancer</i> , 2021, 20, 153-160.	1.0	3
10	A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN G14-186. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3337-3348.	2.0	16
11	Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 74-81.	0.6	36
12	High-Risk Features Are Prognostic in dMMR/MSI-H Stage II Colon Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 755113.	1.3	7
13	Role of Resection of the Primary in Metastatic Well-Differentiated Neuroendocrine Tumors. <i>Pancreas</i> , 2021, 50, 1382-1391.	0.5	2
14	Predictive and Prognostic Effects of Primary Tumor Size on Colorectal Cancer Survival. <i>Frontiers in Oncology</i> , 2021, 11, 728076.	1.3	10
15	The Impact of Genetic Counseling Educational Tools on Patients's Knowledge of Molecular Testing Terminology. <i>Journal of Cancer Education</i> , 2020, 35, 864-870.	0.6	8
16	Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials. <i>Cancer</i> , 2020, 126, 575-582.	2.0	65
17	In-hospital 30-day mortality for older patients with pancreatic cancer undergoing pancreaticoduodenectomy. <i>Journal of Geriatric Oncology</i> , 2020, 11, 660-667.	0.5	13
18	Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy. <i>Oncologist</i> , 2020, 25, e528-e535.	1.9	44

#	ARTICLE	IF	CITATIONS
19	Clinicopathological features and survival outcomes of rare histologic variants of gallbladder cancer. <i>Journal of Surgical Oncology</i> , 2020, 121, 294-302.	0.8	8
20	Survival outcome of adjuvant chemotherapy in deficient mismatch repair stage III colon cancer. <i>Cancer</i> , 2020, 126, 4136-4147.	2.0	6
21	Phase I safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma. <i>British Journal of Cancer</i> , 2020, 123, 1228-1234.	2.9	6
22	In Reply. <i>Oncologist</i> , 2020, 25, e2021-e2021.	1.9	0
23	Impact of Genomic Mutation and Timing of Y90 Radioembolization in Colorectal Liver Metastases. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 1006-1014.	0.9	12
24	Young Adults With Pancreatic Cancer. <i>Pancreas</i> , 2020, 49, 341-354.	0.5	12
25	A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 2497-2505.	3.2	9
26	Radiation as a Single-Modality Treatment in Localized Pancreatic Cancer. <i>Pancreas</i> , 2020, 49, 822-829.	0.5	2
27	Blood-Based Next-Generation Sequencing Analysis of Appendiceal Cancers. <i>Oncologist</i> , 2020, 25, 414-421.	1.9	11
28	Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy. <i>JCI Insight</i> , 2020, 5, .	2.3	31
29	Blood-based next-generation sequencing analysis of neuroendocrine neoplasms. <i>Oncotarget</i> , 2020, 11, 1749-1757.	0.8	29
30	<p>Clinical outcomes of rare hepatocellular carcinoma variants compared to pure hepatocellular carcinoma</p>. <i>Journal of Hepatocellular Carcinoma</i> , 2019, Volume 6, 119-129.	1.8	15
31	Analysis of racial disparities in the treatment and outcomes of colorectal cancer in young adults. <i>Cancer Epidemiology</i> , 2019, 63, 101618.	0.8	26
32	Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms. <i>British Journal of Cancer</i> , 2019, 121, 809-818.	2.9	232
33	Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy. <i>BMC Cancer</i> , 2019, 19, 857.	1.1	88
34	Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer. <i>International Journal of Cancer</i> , 2019, 145, 1529-1537.	2.3	46
35	Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials. <i>Investigational New Drugs</i> , 2019, 37, 1198-1206.	1.2	11
36	Clinical Outcomes of Small Bowel Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2019, 18, 257-268.	1.0	24

#	ARTICLE	IF	CITATIONS
37	Induction Therapy in Localized Pancreatic Cancer. <i>Pancreas</i> , 2019, 48, 913-919.	0.5	7
38	High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study. <i>Oncologist</i> , 2019, 24, 911-920.	1.9	39
39	Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer. <i>Cancer</i> , 2019, 125, 57-67.	2.0	15
40	The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy. <i>Cancer</i> , 2019, 125, 127-134.	2.0	120
41	Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases. <i>Cancer</i> , 2018, 124, 1992-2000.	2.0	17
42	Evaluation of Treatment Patterns and Survival Outcomes in Elderly Pancreatic Cancer Patients: A Surveillance, Epidemiology, and End Results-Medicare Analysis. <i>Oncologist</i> , 2018, 23, 704-711.	1.9	15
43	Gastric squamous cell carcinoma and gastric adenosquamous carcinoma, clinical features and outcomes of rare clinical entities: a National Cancer Database (NCDB) analysis. <i>Journal of Gastrointestinal Oncology</i> , 2018, 10, 85-94.	0.6	24
44	Incidence and Survival of Appendiceal Mucinous Neoplasms. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 569-573.	0.6	45
45	Novel synthetic curcumin analogs as potent antiangiogenic agents in colorectal cancer. <i>Molecular Carcinogenesis</i> , 2017, 56, 288-299.	1.3	35
46	Discussing molecular testing in oncology care: Comparing patient and physician information preferences. <i>Cancer</i> , 2017, 123, 1610-1616.	2.0	14
47	Using Metaphors to Explain Molecular Testing to Cancer Patients. <i>Oncologist</i> , 2017, 22, 445-449.	1.9	9
48	Inhibiting heat shock protein 90 and the ubiquitin-proteasome pathway impairs metabolic homeostasis and leads to cell death in human pancreatic cancer cells. <i>Cancer</i> , 2017, 123, 4924-4933.	2.0	20
49	Appendiceal Mucinous Neoplasms: Diagnosis and Management. <i>Oncologist</i> , 2017, 22, 1107-1116.	1.9	131
50	Non-ampullary duodenal carcinomas: clinicopathologic analysis of 47 cases and comparison with ampullary and pancreatic adenocarcinomas. <i>Modern Pathology</i> , 2017, 30, 255-266.	2.9	36
51	TTF-1 Expression in Rectal Adenocarcinoma: A Case Report and Review of the Literature. <i>Case Reports in Oncology</i> , 2017, 9, 747-751.	0.3	8
52	The Future Prospects of Immune Therapy in Gastric and Esophageal Adenocarcinoma. <i>Journal of Clinical Medicine</i> , 2016, 5, 100.	1.0	10
53	A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458). <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 296-303.	0.4	61
54	Adenocarcinoma ex-goblet cell carcinoid (appendiceal-type crypt cell adenocarcinoma) is a morphologically distinct entity with highly aggressive behavior and frequent association with peritoneal/intra-abdominal dissemination: an analysis of 77 cases. <i>Modern Pathology</i> , 2016, 29, 1243-1253.	2.9	53

#	ARTICLE	IF	CITATIONS
55	Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib. <i>European Journal of Cancer</i> , 2016, 52, 109-119.	1.3	38
56	Inhibition of NF- κ B translocation by curcumin analogs induces G0/G1 arrest and downregulates thymidylate synthase in colorectal cancer. <i>Cancer Letters</i> , 2016, 373, 227-233.	3.2	63
57	Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer. <i>Oncologist</i> , 2016, 21, 178-187.	1.9	47
58	Appendiceal Neuroendocrine, Goblet and Signet-Ring Cell Tumors: A Spectrum of Diseases with Different Patterns of Presentation and Outcome. <i>Cancer Research and Treatment</i> , 2016, 48, 596-604.	1.3	30
59	Management and Outcomes of Hospitalized Patients With Primary Neuroendocrine Tumor and Non-Neuroendocrine Tumor Appendiceal Cancers in the United States. <i>World Journal of Oncology</i> , 2015, 6, 349-354.	0.6	0
60	Hyperthermic Intraperitoneal Chemotherapy Following Cytoreductive Surgery Improves Outcome in Patients With Primary Appendiceal Mucinous Adenocarcinoma: A Pooled Analysis From Three Tertiary Care Centers. <i>Oncologist</i> , 2015, 20, 907-914.	1.9	25
61	Peptide Vaccines for Treatment of Colon Cancer: Have We Made Progress?. <i>Current Colorectal Cancer Reports</i> , 2014, 10, 477-486.	1.0	0
62	Treatment utilization and surgical outcome of ampullary and duodenal adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2014, 109, 556-560.	0.8	12
63	Markers of resistance to anti-EGFR therapy in colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2013, 4, 308-18.	0.6	45